StockData
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

GILEAD SCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$153.07−3.12 (-2.00%)

Close on Oct 19, 2026

Market cap
$190.27B
P/E (TTM)
–
Dividend yield
2.06%

Earnings

Next report expected Oct 29, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 4, 2026After market close$7.80B$-8.45$-6.75
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026After market close$6.96B$1.61$2.03
Q4 FY2025
Ended Dec 31, 2025
Feb 10, 2026After market close$7.90B$1.74$1.86
Q3 FY2025
Ended Sep 30, 2025
Oct 30, 2025After market close$7.80B$2.43$2.47
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025After market close$7.10B$1.56$2.01
Q1 FY2025
Ended Mar 31, 2025
Apr 24, 2025After market close$6.70B$1.04$1.81
Q4 FY2024
Ended Dec 31, 2024
Feb 11, 2025After market close$7.60B$1.42$1.90
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024After market close$7.50B$1.00$2.02
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
Apr 25, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Feb 6, 2024After market close–––

Company guidance

Outlook given with results on Aug 4, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Non-GAAP diluted loss per sharenon-GAAPfull year 2026$-0.65 to $-0.30Raised
Diluted loss per shareGAAPfull year 2026$-3.75 to $-3.40Lowered
GAAP projected product gross marginGAAP202679%Maintained
Non-GAAP projected product gross marginnon-GAAP202687%Maintained
GAAP projected operating income (loss)GAAP2026-$2.25B to -$1.85BLowered
Non-GAAP projected operating incomenon-GAAP2026$2.90B to $3.30BRaised
Non-GAAP projected effective tax ratenon-GAAP2026115% to 140%Lowered
GAAP projected effective tax rateGAAP2026-90% to -80%Raised
Product salesGAAPfull year 2026$30.10B to $30.40BNew
Product sales excluding VekluryGAAPfull year 2026$29.80B to $30.10BLowered
VekluryGAAPfull year 2026$300.00MLowered

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Gilead Sciences filed with the SEC